logo
ProjectOngoing

Engineering B cells to fight cancer

Sector: Residential • Location: Israel

Source: EU Funding & Tenders Portal

B cells have an important role in the immune response against cancer. Tumor specific B cells in tertiary lymphoid structures and anti-tumor antibodies in the plasma are associated with a favorable prognosis and with an improved response to checkpoint inhibition in different sarcomas and carcinomas. Antigen specific B cells home to tumors and prolong survival in mice, while B cell based vaccines al

Status
Under Construction
Sector
Residential, Education, Automotive
Location
Israel
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Engineering B cells to fight cancer

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Engineering B cells to fight cancer” is an infrastructure initiative in the Residential sector, located in Israel. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ongoing

Taiyo status

Under Construction

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

B cells have an important role in the immune response against cancer. Tumor specific B cells in tertiary lymphoid structures and anti-tumor antibodies in the plasma are associated with a favorable prognosis and with an improved response to checkpoint inhibition in different sarcomas and carcinomas. Antigen specific B cells home to tumors and prolong survival in mice, while B cell based vaccines allow durable anti-tumor activity in cervical cancer patients. We have recently demonstrated both ex vivo and in vivo B cell engineering for the expression of anti-HIV antibodies. Here, we propose a novel cancer immunotherapy approach based on engineered B cells. In particular, we use CRISPR/Cas9 and AAV to target the integration of anti-tumor antibody genes into the IgH locus. In diverse tumor models, we plan to demonstrate localized B cell activation upon antigen engagement. The B cells will exert multiple anti-tumor effects. Secreted antibodies will induce ADCC, CDC and ADCP. In addition, a polyclonal T cell response with epitope spreading will be facilitated by engineered B cells acting as APCs as well as by antibodies forming immune complexes to be taken up by dendritic cells and macrophages for cross-presentation. The B cell will be co-engineered to locally secrete additional immune effectors upon activation. These include: stimulatory cytokines, BiTEs, checkpoint inhibitors, CD40/27 agonists and cell penetrating nanobodies. Localized secretion is predicted to increase efficacy while reducing systemic toxicities. When targeting self-antigens, B cells will be engineered to co-express a CAR, relaying CD40 or TLR signals for T cell independent B cell activation and allowing allogeneic therapy. We will further demonstrate in vivo B cell engineering for increased scalability, and ensure safety using a suicide cassette for inducible B cell elimination. B cell engineering is thus a flexible and robust platform technology that may revolutionize cancer immunotherapy.

Location

Country

Israel

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Residential, Education, Automotive

Article published date

2025-12-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project